Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-2 R beta

IL-2 R beta

Brief Information

Name:Interleukin-2 receptor alpha chain
Target Synonym:Insulin-Dependent Diabetes Mellitus 10,Interleukin-2 Receptor alpha Subunit,TAC antigen,p55,IL2-RA,Interleukin-2 receptor subunit alpha,IL-2-RA,IL-2R subunit alpha,IL2RA,Interleukin 2 Receptor Subunit Alpha,Interleukin 2 Receptor, Alpha,IL-2 Receptor Subunit Alpha,CD25 Antigen,IDDM10,IMD41,TCGFR,CD25,IL2R
Number of Launched Drugs:5
Number of Drugs in Clinical Trials:7
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

CD2-H5221-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Human IL-2 R beta, His Tag (SPR verified) (Cat. No. CD2-H5221) inhibits the IL-15-dependent proliferation of Mo7e cells. The EC50 for this effect is 0.38-0.45 µg/mL (Routinely tested).

ILB-H5253-SPR
Human_FcRn_Heterodimer_Protein_SPR

Human IL-2 R beta, Fc Tag (Cat. No. ILB-H5253) captured on CM5 chip via anti-human IgG Fc antibody can bind IL-2, Tag Free (Cat. No. IL2-H4113) with an affinity constant of 0.473 μM as determined in a SPR assay (Biacore T200) (QC tested).

CD2-H5221-SPR
Human_FcRn_Heterodimer_Protein_SPR

Human IL-2 R beta, His Tag (SPR verified) (Cat. No. CD2-H5221) captured on CM5 chip via anti-His antibody, can bind Human IL-2, Tag Free (Cat. No. IL2-H4113) with an affinity constant of 0.525 μM as determined in a SPR assay (Biacore T200) (QC tested).

Synonym Name

IL2RB,RP5-1170K4.6,CD122,P70-75

Background

Interleukin-2 receptor (IL-2R) is a heterotrimeric protein expressed on the surface of certain immune cells, such as lymphocytes, that binds and responds to a cytokine called IL-2. The IL-2R is made up of 3 subunits - α (CD25), β (CD122) and γ (CD132) - non-covalently associating. The α and β chains are involved in binding IL-2, while signal transduction following cytokine interaction is carried out by the γ-chain, along with the β subunit. CD122 is also known as IL2R beta, is a member of the type I cytokine receptor family. CD122 is the receptor for interleukin-2 and is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2.

Clinical and Translational Updates

Related Molecule

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Denileukin diftitox E-7272; E-7777; DAB-389; LY-335348; DAB389IL-2 Approved Eisai Co Ltd Ontak, Onzar United States Lymphoma, T-Cell, Cutaneous Eisai Inc 1999-02-05 Lymphoma, T-Cell, Peripheral; Lymphoma, B-Cell; Leukemia; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma Details
Basiliximab CHT-25; chRFT5; CHI-621; SDZ-CHI-621 Approved Novartis Pharma Ag 舒莱, Simulect Japan Rejection of organ transplantation Novartis Pharma Ag 1998-05-12 Rejection of renal transplantation; Rejection of organ transplantation; Colitis, Ulcerative; Uveitis Details
Daclizumab R-35; BIIB-019; RO-247375 Approved Abbvie Inc, Biogen Inc, F. Hoffmann-La Roche Ltd Zinbryta, Zenapax United States Multiple Sclerosis Biogen Inc 1997-12-10 Multiple Sclerosis, Relapsing-Remitting; Gastrointestinal Diseases; Inflammatory Bowel Diseases; Multiple Sclerosis; Rejection of organ transplantation; Asthma; Colitis, Ulcerative Details
Daclizumab biosimilar (Shanghai CP Guojian) Approved Shanghai Cp Guojian Pharmaceutical Co Ltd 健尼哌 Mainland China Rejection of renal transplantation null 2011-01-12 Rejection of renal transplantation Details
Recombinant Human Interleukin-2(Ⅰ) (Liaoning Satellite Biological Products) Approved Liaoning Satellite Biological Products Research Institute (Limited) Mainland China Neoplasms Liaoning Satellite Biological Products Research Institute (Limited) 2002-02-04 Neoplasms Details
Denileukin diftitox E-7272; E-7777; DAB-389; LY-335348; DAB389IL-2 Approved Eisai Co Ltd Ontak, Onzar United States Lymphoma, T-Cell, Cutaneous Eisai Inc 1999-02-05 Lymphoma, T-Cell, Peripheral; Lymphoma, B-Cell; Leukemia; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma Details
Basiliximab CHT-25; chRFT5; CHI-621; SDZ-CHI-621 Approved Novartis Pharma Ag 舒莱, Simulect Japan Rejection of organ transplantation Novartis Pharma Ag 1998-05-12 Rejection of renal transplantation; Rejection of organ transplantation; Colitis, Ulcerative; Uveitis Details
Daclizumab R-35; BIIB-019; RO-247375 Approved Abbvie Inc, Biogen Inc, F. Hoffmann-La Roche Ltd Zinbryta, Zenapax United States Multiple Sclerosis Biogen Inc 1997-12-10 Multiple Sclerosis, Relapsing-Remitting; Gastrointestinal Diseases; Inflammatory Bowel Diseases; Multiple Sclerosis; Rejection of organ transplantation; Asthma; Colitis, Ulcerative Details
Daclizumab biosimilar (Shanghai CP Guojian) Approved Shanghai Cp Guojian Pharmaceutical Co Ltd 健尼哌 Mainland China Rejection of renal transplantation null 2011-01-12 Rejection of renal transplantation Details
Recombinant Human Interleukin-2(Ⅰ) (Liaoning Satellite Biological Products) Approved Liaoning Satellite Biological Products Research Institute (Limited) Mainland China Neoplasms Liaoning Satellite Biological Products Research Institute (Limited) 2002-02-04 Neoplasms Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Basiliximab biobetter (Mabtech/Sorrento) STI-003 Phase 3 Clinical Taizhou Maibo Taike Biotechnology Co Ltd Autoimmune Diseases Details
Anti-interleukin-2 receptor monoclonal antibody Mikbeta1 HuMikβ1-1 Phase 1 Clinical F. Hoffmann-La Roche Ltd, National Institutes Of Health Leukemia, Lymphoid Details
RO-7296682 RO-7296682; RG-6292 Phase 1 Clinical F. Hoffmann-La Roche Ltd Solid tumours Details
Inolimomab B-B10; BT-563; MAb-BT-563 Phase 3 Clinical Eusa Pharma, Jazz Pharmaceuticals Graft vs Host Disease Details
XmAb-564 XmAb-564; XmAb-27564 Phase 1 Clinical Xencor Autoimmune Diseases Details
Camidanlumab tesirine ADCT-301 Phase 2 Clinical Genmab, Adc Therapeutics Hodgkin Disease; Melanoma; Carcinoma, Non-Small-Cell Lung; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Fallopian Tube Neoplasms; Colorectal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Urinary Bladder Neoplasms; Solid tumours; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Ovarian Neoplasms Details
MDNA-11 MDNA-11; MDNA11 Phase 2 Clinical Medicenna Therapeutics Corp Cholangiocarcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Uterine Neoplasms; Carcinoma, Squamous Cell; Gallbladder Neoplasms; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Sarcoma; Solid tumours; Urinary Bladder Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Merkel Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Stomach Neoplasms; Ovarian Neoplasms; Biliary Tract Neoplasms Details
ANV-419 Phase 2 Clinical Anaveon AG Solid tumours; Multiple Myeloma Details
In 111-DOTA-Basiliximab Phase 1 Clinical City Of Hope National Medical Center Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute Details
90Y Basiliximab Phase 2 Clinical City Of Hope National Medical Center Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin Details
PT-101 MK-6194; PT-101 Phase 1 Clinical Pandion Therapeutics Autoimmune Diseases; Colitis, Ulcerative Details
RM-1995 RM-1995 Phase 1 Clinical Rakuten Medical Inc Squamous Cell Carcinoma of Head and Neck; Carcinoma, Squamous Cell Details
Basiliximab biobetter (Mabtech/Sorrento) STI-003 Phase 3 Clinical Taizhou Maibo Taike Biotechnology Co Ltd Autoimmune Diseases Details
Anti-interleukin-2 receptor monoclonal antibody Mikbeta1 HuMikβ1-1 Phase 1 Clinical F. Hoffmann-La Roche Ltd, National Institutes Of Health Leukemia, Lymphoid Details
RO-7296682 RO-7296682; RG-6292 Phase 1 Clinical F. Hoffmann-La Roche Ltd Solid tumours Details
Inolimomab B-B10; BT-563; MAb-BT-563 Phase 3 Clinical Eusa Pharma, Jazz Pharmaceuticals Graft vs Host Disease Details
XmAb-564 XmAb-564; XmAb-27564 Phase 1 Clinical Xencor Autoimmune Diseases Details
Camidanlumab tesirine ADCT-301 Phase 2 Clinical Genmab, Adc Therapeutics Hodgkin Disease; Melanoma; Carcinoma, Non-Small-Cell Lung; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Fallopian Tube Neoplasms; Colorectal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Urinary Bladder Neoplasms; Solid tumours; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Ovarian Neoplasms Details
MDNA-11 MDNA-11; MDNA11 Phase 2 Clinical Medicenna Therapeutics Corp Cholangiocarcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Uterine Neoplasms; Carcinoma, Squamous Cell; Gallbladder Neoplasms; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Sarcoma; Solid tumours; Urinary Bladder Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Merkel Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Stomach Neoplasms; Ovarian Neoplasms; Biliary Tract Neoplasms Details
ANV-419 Phase 2 Clinical Anaveon AG Solid tumours; Multiple Myeloma Details
In 111-DOTA-Basiliximab Phase 1 Clinical City Of Hope National Medical Center Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute Details
90Y Basiliximab Phase 2 Clinical City Of Hope National Medical Center Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin Details
PT-101 MK-6194; PT-101 Phase 1 Clinical Pandion Therapeutics Autoimmune Diseases; Colitis, Ulcerative Details
RM-1995 RM-1995 Phase 1 Clinical Rakuten Medical Inc Squamous Cell Carcinoma of Head and Neck; Carcinoma, Squamous Cell Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message